NCT05507411View on ClinicalTrials.gov

Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

August 3, 2022

Primary Completion Date

April 30, 2024

Study Completion Date

April 30, 2027

Conditions
Esophageal Squamous Cell Carcinoma
Interventions
RADIATION

Neoadjuvant Radiotherapy

41.4Gy/23F

DRUG

Neoadjuvant Chemotherapy

Paclitaxel for Injection （Albumin Bound): 50mg/m\^2 QW Carboplatin: AUC=2 QW

DRUG

Immunotherapy

Camrelizumab 200mg Q3W

Trial Locations (3)

Unknown

NOT_YET_RECRUITING

The First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU), Hanzhou

RECRUITING

Zhejiang Cancer Hospital, Hanzhou

NOT_YET_RECRUITING

Ningbo Medical Center Lihuili Hospital, Ningbo

All Listed Sponsors
collaborator

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

lead

Zhejiang Cancer Hospital

OTHER